Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects
Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes. DCM causes microvascular disease, myocardial metabolic disorde...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-01-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0063 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825201937469931520 |
|---|---|
| author | Feng Zhang Zhuqing Li Yanxin Wang Chao Li Chengzhi Lu |
| author_facet | Feng Zhang Zhuqing Li Yanxin Wang Chao Li Chengzhi Lu |
| author_sort | Feng Zhang |
| collection | DOAJ |
| description | Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes. DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure. Recent studies have highlighted the crucial roles of mitochondrial dysfunction in the pathogenesis of DCM, including aspects such as glucose-lipid metabolic disorder, oxidative stress damage, calcium regulation disorder, respiratory chain uncoupling, kinetic imbalance, and mitochondrial DNA damage. Increasing numbers of targets and drugs are being identified to ameliorate mitochondrial dysfunction and consequently slow DCM progression. This article reviews the newly identified targets and drugs in the past decade, to provide new insights for DCM prevention and treatment. |
| format | Article |
| id | doaj-art-b3896df70b764911a803a111cd5a0fb8 |
| institution | Kabale University |
| issn | 2009-8618 2009-8782 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Cardiovascular Innovations and Applications |
| spelling | doaj-art-b3896df70b764911a803a111cd5a0fb82025-02-07T17:00:11ZengCompuscript LtdCardiovascular Innovations and Applications2009-86182009-87822025-01-0110199210.15212/CVIA.2024.0063Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and ProspectsFeng Zhang0Zhuqing Li1Yanxin Wang2Chao Li3Chengzhi Lu41The First Central Clinical School, Tianjin Medical University, Tianjin 300070, China2Department of Cardiology, Tianjin First Center Hospital, Tianjin 300192, China1The First Central Clinical School, Tianjin Medical University, Tianjin 300070, China2Department of Cardiology, Tianjin First Center Hospital, Tianjin 300192, China2Department of Cardiology, Tianjin First Center Hospital, Tianjin 300192, ChinaDiabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes. DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure. Recent studies have highlighted the crucial roles of mitochondrial dysfunction in the pathogenesis of DCM, including aspects such as glucose-lipid metabolic disorder, oxidative stress damage, calcium regulation disorder, respiratory chain uncoupling, kinetic imbalance, and mitochondrial DNA damage. Increasing numbers of targets and drugs are being identified to ameliorate mitochondrial dysfunction and consequently slow DCM progression. This article reviews the newly identified targets and drugs in the past decade, to provide new insights for DCM prevention and treatment.https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0063 |
| spellingShingle | Feng Zhang Zhuqing Li Yanxin Wang Chao Li Chengzhi Lu Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects Cardiovascular Innovations and Applications |
| title | Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects |
| title_full | Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects |
| title_fullStr | Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects |
| title_full_unstemmed | Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects |
| title_short | Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects |
| title_sort | mitochondrial dysfunction as a therapeutic target in diabetic cardiomyopathy progress and prospects |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0063 |
| work_keys_str_mv | AT fengzhang mitochondrialdysfunctionasatherapeutictargetindiabeticcardiomyopathyprogressandprospects AT zhuqingli mitochondrialdysfunctionasatherapeutictargetindiabeticcardiomyopathyprogressandprospects AT yanxinwang mitochondrialdysfunctionasatherapeutictargetindiabeticcardiomyopathyprogressandprospects AT chaoli mitochondrialdysfunctionasatherapeutictargetindiabeticcardiomyopathyprogressandprospects AT chengzhilu mitochondrialdysfunctionasatherapeutictargetindiabeticcardiomyopathyprogressandprospects |